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We obtained health surveillance epidemiologic data on 
malaria among French military personnel deployed to French 
Guiana during 1998–2008. Incidence of Plasmodium vivax 
malaria increased and that of P. falciparum remained stable. 
This new epidemiologic situation has led to modiﬁ  cation of 
malaria treatment for deployed military personnel.
F
rench Guiana is a French Province located on the northern 
coast of South America that had 221,500 inhabitants 
in 2008 (1). Malaria is endemo-epidemic to the Amazon 
basin. Since 2000, the annual number of Plasmodium 
falciparum and P. vivax malaria cases in French Guiana 
has ranged from 3,500 to 4,500 (2). Approximately 3,000 
French military personnel are deployed annually in French 
Guiana, and malaria occasionally affects their operational 
capabilities.
Only military personnel on duty in the Amazon basin 
are required to take malaria chemoprophylaxis; personnel 
deployed in coast regions are not. Until February 2001, the 
chemoprophylaxis regimen consisted of chloroquine (100 
mg/d) and proguanil (200 mg/d). During March 2001–
October 2003, meﬂ  oquine (250 mg/wk) was used. Since 
November, 2003 malaria chemoprophylaxis has been 
doxycycline (100 mg/d), which is initiated on arrival in the 
Amazon basin. All chemoprophylaxis is continued until 4 
weeks after departure. Because of the absence of marketing 
authorization as chemoprophylaxis by the French 
Medicines Agency, primaquine was not used until recently. 
Other individual and collective protective measures did not 
change during 1998–2008.
Despite the availability of chemoprophylaxis, since 
2003, several malaria outbreaks have been identiﬁ  ed after 
operations against illegal mining in the Amazon basin (3,4). 
The purpose of those studies was to describe outbreaks 
and determine factors related to malaria cases. We report 
French military health surveillance epidemiologic data 
on malaria among military personnel deployed to French 
Guiana during 1998–2008.
The Study
Epidemiologic malaria surveillance in French 
Armed Forces consists of continuous and systematic 
collection, analysis, interpretation, and feedback of 
epidemiologic data from all military physicians (online 
Technical Appendix, www.cdc.gov/EID/content/17/7/
1280-Techapp.pdf). Malaria is deﬁ  ned as any pathologic 
event or symptom associated with conﬁ  rmed parasitologic 
evidence (Plasmodium spp. on a blood smear, a positive 
quantitative buffy coat malaria diagnosis test result, or 
a positive malaria rapid diagnosis test result) contracted 
in French Guiana. A case occurring in a person during 
or after a stay in French Guiana without a subsequent 
stay in another malaria-endemic area was assumed to 
be contracted in French Guiana. Each malaria attack 
was considered a separate case. Equal information was 
available for the entire 11-year study period. Data from 
weekly reports and malaria-speciﬁ  c forms were used for 
analysis.
Indicators are expressed as annual incidence and 
annual incidence rate. The denominator of the annual 
incidence rate is the average number of military personnel 
at risk for malaria during a given year.
Statistical analysis was performed by using Epi Info 
6.04dfr (Centers for Disease Control and Prevention, 
Atlanta, GA, USA). Comparisons over time were made 
by using the χ2 test for trend and between groups by using 
the Kruskal-Wallis test. A p value <0.05 was considered 
signiﬁ  cant.
The incidence rate for malaria cases among French 
military personnel deployed to French Guiana has 
increased since 1998 (p<0.001). P. falciparum incidence 
has remained stable (p = 0.10), and P. vivax incidence has 
increased (p<0.001) (Figure). In 2007 and 2008, French 
military personnel in French Guiana represented only 23.0% 
and 22.2% of those deployed to malaria-endemic regions. 
However, most reported malaria cases were contracted in 
this region (50.0% and 62.9%, respectively, of all cases). P. 
vivax was responsible for most malaria attacks reported in 
French Guiana (Table). The proportion of malaria attacks 
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caused by P. vivax increased from 44% to 84% (p<0.001) 
during the study period.
In 2008, among the 264 reported cases, 221 were 
temporarily unavailable for duty. Median lost work days 
were lower for attacks of P.  vivax malaria than for P. 
falciparum malaria (5 days/attack, interquartile range 4–7 
days/attack vs. 7 days/attack, interquartile range 5–10 days/
attack; p = 0.006)
Among 264 malaria cases contracted in French Guiana, 
39.4% were in persons who had reported >1 malaria attack 
in the previous 6 months. Among the 221 P. vivax malaria 
cases, 45.5% were in persons who had already reported 
>1 P. vivax malaria attack in the previous 6 months. In 
2008, among those required to take chemoprophylaxis 
(i.e., during a mission to the Amazon basin and 28 days 
after the mission), 45.0% admitted not taking their 
chemoprophylaxis within 8 days before onset of symptoms.
Conclusions
P. vivax malaria attacks have resulted in a substantial 
number of lost work days and have adversely affected 
operational readiness of military personnel. Despite 
availability of appropriate chemoprophylaxis, since 1998, 
French Armed Forces have been affected by an increase 
in incidence of P. vivax malaria. Several causes of this 
increase have been hypothesized.
First, epidemiologic trends for all-cause malaria in 
French Guiana and overall reported malaria incidence has 
not changed substantially since the end of the 20th century: 
≈4 000 cases were reported annually during the 1990s (5) 
and 3,500–4,500 were reported during 2008 (2). However, 
the proportion of P.  vivax malaria has increased from 
20% of cases in the 1990s (6) to 56.1% during September 
2003–February 2004 among patients at the Cayenne Public 
Hospital (7). Furthermore, 70% of malaria cases diagnosed 
in 2006 among French travelers returning from French 
Guiana were caused by P. vivax (8). One explanation for 
this parasitologic evolution may involve immigration from 
Brazil and Suriname to illegal gold-mining areas in the 
Amazon basin of French Guiana (2,6). These immigrating 
populations brought P. vivax from high-prevalence regions 
to an area where an efﬁ  cient vector for malaria, Anopheles 
darlingi mosquitoes, was present (9). Changes in weather 
patterns and regional infrastructure could also explain this 
increase.
Second, military missions have intensiﬁ  ed. In 2008, a 
police and military operation to reduce illegal gold-panning 
activities in the Amazon basin occurred in French Guiana. 
This operation might explain the 2008 peak in the incidence 
rate. Since 2002, these operations have resulted in several 
outbreaks among forces in French Guiana, especially in 
2003 and 2005 (2,3).
Third, deﬁ   ciencies have occurred in implementing 
individual and collective protective measures. These 
military operations were conducted by personnel from 
French Guiana or France, few had any rainforest experience. 
Despite extensive training, instructions were clearly not 
followed, as demonstrated by a 45% noncompliance rate 
for chemoprophylaxis.
P. vivax has accounted for >80% of reported malaria 
cases in French Guiana for the past 3 years. In addition, 
relapses of P. vivax malaria occur in the absence of radical 
treatment. In 2008, 45.5% of persons with P. vivax malaria 
had already reported >1 P. vivax malaria attack in the past 
6 months. Although the P. vivax malaria mortality rate is 
low, the effect of P. vivax malaria on force operational 
readiness is high because relapses decrease the availability 
of military personnel. In addition, P. vivax malaria can be 
severe, despite its reputation as a mild form of malaria 
(10). Since 2009, to reduce the number of relapses, a 
French Ministry of Defense circular has recommended 
treatment with primaquine for 2 or 3 weeks after a ﬁ  rst 
attack of P. vivax malaria. Studies of the use of primaquine 
chemoprophylaxis are ongoing (11–13).
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Figure. Incidence of malaria cases among French Armed Forces, 
by Plasmodium species, French Guiana, 1998–2008.
Table. Cases of Plasmodium spp. malaria among French Armed 











1998 41 35 0 1 3
1999 56 71 1 0 4
2000 36 48 0 2 5
2001 7 38 0 3 1
2002 19 40 1 2 0
2003 54 95 0 0 0
2004 22 72 1 3 0
2005 50 158 3 1 0
2006 29 123 0 2 0
2007 20 137 1 0 0
2008 44 221 0 0 0
*Cases of malaria caused by 2 parasites (co-infections) were included for 
each involved species. In conclusion, the incidence of P.  vivax malaria is 
increasing in French Guiana, especially in French Armed 
Forces. The incidence of P. falciparum malaria remains 
stable. This new epidemiologic ﬁ   nding can affect the 
level of individual health and operational capabilities. 
Performance of vector evaluation studies and control in the 
regions could be another possible intervention.
Acknowledgments
We thank Mark Dearden for assistance with the preparation 
of this report.
This study was supported by the French Medical Forces.
Dr Queyriaux is a physician at the Institut de Médicine 
Tropicale du Service de Santé des Armées, Marseille, France. His 
research interests are public health and epidemiology.
References
  1.   Institut National de la Statistique et des Études Économiques. Popu-
lation des régions au 1 Janvier [cited 2009 Nov 23]. http://www.
insee.fr/fr/themes/tableau.asp.
  2.   Carme B, Ardillon V, Girod R, Grenier C, Joubert M, Djossou F, 
et al. Update on the epidemiology of malaria in French Guiana [in 
French]. Med Trop (Mars). 2009;69:19–25.
  3.   Michel R, Ollivier L, Meynard JB, Guette C, Migliani R, Boutin JP. 
Outbreak of malaria among policemen in French Guiana. Mil Med. 
2007;172:977–81.
  4.   Verret C, Cabianca B, Haus-Cheymol R, Laﬁ  lle JJ, Loran-Haranqui 
G, Spiegel A. Malaria outbreak in troops returning from French Gui-
ana. Emerg Infect Dis. 2006;12:1794–5.
  5.   Juminer B, Robin Y, Pajot FX, Eutrope R. Malaria pattern in French 
Guiana [in French]. Med Trop (Mars). 1981;41:135–46.
    6.    Cochet P, Deparis X, Morillon M, Louis FJ. Malaria in French 
Guiana: between tradition and modernism [in French]. Med Trop 
(Mars). 1996;56:185–8.
  7.   de Lavaissiere M, d’Ortenzio E, Dussart P, Fontanella JM, Djos-
sou F, Carme B, et al. Febrile illness at the emergency department 
of Cayenne Hospital, French Guiana. Trans R Soc Trop Med Hyg. 
2008;102:1055–7. doi:10.1016/j.trstmh.2008.06.011
  8.   Behrens RH, Carroll B, Beran J, Bouchaud O, Hellgren U, Hatz C, 
et al. The low and declining risk of malaria in travellers to Latin 
America: is there still an indication for chemoprophylaxis? Malar J. 
2007;6:114. doi:10.1186/1475-2875-6-114
  9.   Girod R, Gaborit P, Carinci R, Issaly J, Fouque F. Anopheles darlingi 
bionomics and transmission of Plasmodium falciparum, Plasmodi-
um vivax and Plasmodium malariae in Amerindian villages of the 
Upper-Maroni Amazonian forest, French Guiana. Mem Inst Oswaldo 
Cruz. 2008;103:702–10. doi:10.1590/S0074-02762008000700013
10.   Picot S. Is Plasmodium vivax still a paradigm for uncomplicated ma-
laria? [in French]. Med Mal Infect. 2006;36:406–13. doi:10.1016/j.
medmal.2006.06.001
11.  Oliver M, Simon F, de Monbrison F, Beavogui AH, Pradines B, 
Ragot C, et al. New use of primaquine for malaria [in French]. Med 
Mal Infect. 2008;38:169–79. doi:10.1016/j.medmal.2008.01.011
12.   Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, et al. 
Double-blind, randomized, placebo-controlled assessment of chloro-
quine/primaquine prophylaxis for malaria in nonimmune Colombian 
soldiers. Clin Infect Dis. 1999;29:199–201. doi:10.1086/520154
13.   Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, et al. 
Primaquine prophylaxis against malaria in nonimmune Colombian 
soldiers: efﬁ  cacy and toxicity. A randomized, double-blind, placebo-
controlled trial. Ann Intern Med. 1998;129:241–4.
Address for correspondence: Benjamin Queyriaux, Département 
d’Épidémiologie et de Santé Publique, Institut de Médicine Tropicale du 
Service de Santé des Armées, Parc du Pharo, Boulevard Charles Livon, 
Marseille 13007, France; email: b.queyriaux@gmail.com
DISPATCHES
1282  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 7, July 2011